Ardelyx (ARDX) AI Stock Analysis

2 Followers

Ardelyx

(BMV:ARDX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Product Revenue GrowthStrong growth across both commercial products demonstrates expanding demand and improving market penetration. Continued prescription and writer gains, particularly for IBSRELA, can support operating leverage and provide a durable base for management’s reaffirmed 2026 revenue targets.

Negative Factors

Elevated LeverageRising leverage reduces financial flexibility while Ardelyx remains unprofitable. A higher debt burden can constrain investment in commercialization and trials, and it increases the consequences if revenue growth slows or the planned profitability milestone is delayed.

Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 717.66M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -12.8
Beta (1Y): 0.27
Revenue Growth: 5.75%
EPS Growth: 17.11%
Country: Mexico
Employees: 489
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ardelyx Business Overview & Revenue Model

Company Description

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both dome...

Ardelyx Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 25, 2027

Earnings Call SentimentPositive

The call was predominantly positive, supported by 19% total product revenue growth, 23% IBSRELA growth, strong demand trends, reaffirmed 2026 guidance, improved net loss, $285.3 million of liquidity, and ahead-of-schedule enrollment in the ACCEL Phase III trial. The main challenges were persistent payer friction, complex XPHOZAH reimbursement dynamics, gross-to-net erosion, recent prescription-data volatility, and continued operating investments. Management remained confident in execution and the path to profitability in 2027.

Positive Updates

Total Product Revenue Growth

Third-quarter product revenue was $125.5 million, compared with $105.5 million in the same period last year, representing 19% year-over-year growth. IBSRELA and XPHOZAH generated over $125 million in combined revenue.

Negative Updates

Persistent Payer and Prior Authorization Friction

Payer friction remains a challenge for IBSRELA patients and physicians. Management said there is no single solution or magic bullet, that improvements will occur through meaningful steps over time, and that a dramatic inflection in prior authorization rates should not be anticipated.

Company Guidance

Ardelyx reaffirmed full year 2026 IBSRELA guidance of $350 million to $370 million, representing annual growth of more than 30% at the midpoint, and full year 2026 XPHOZAH revenue guidance of $110 million to $120 million; full year 2026 operating expenses are expected to be below $500 million, with profitability expected to occur in 2027, supported by a greater than 95% gross profit margin, while the company’s long-term view is achieving $1 billion in annual revenue for IBSRELA and it expects to report ACCEL top line results in the second half of 2027.

Ardelyx Risk Analysis

Ardelyx disclosed 53 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Our business may be affected by the evolving regulatory framework for AI TechnologiesQ2, 2026

Ardelyx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ARDX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRMD	78Outperform	$414.66M	2.21	44.64%	―	280.50%	210.82%
PHAT	59Neutral	$426.78M	-5.10	29.66%	―	86.75%	72.98%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DMAC	51Neutral	$504.74M	-13.00	-77.68%	―	―	-3.42%
LXRX	46Neutral	$792.52M	-12.25	-37.80%	―	-45.62%	21.16%
ENTA	41Neutral	$320.38M	-4.56	-61.84%	―	0.70%	44.24%

* Healthcare Sector Average

Performance Comparison

MX:ARDX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ARDX	Ardelyx Inc	56.90	-65.30	-53.44%
CRMD	Cormedix Inc.	5.32	-5.87	-52.46%
LXRX	Lexicon Pharmaceuticals	1.78	0.22	14.10%
ENTA	Enanta Pharmaceuticals	11.00	-1.04	-8.64%
DMAC	Diamedica Therapeutics	9.36	2.97	46.48%
PHAT	Phathom Pharmaceuticals, Inc.	5.25	-9.11	-63.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ardelyx AI Stock Analysis